Intellectual Property Law
New Matter SPRING 2020, Volume 45, Number 1
Content
- Broad Institute Crispr: Epo Patent Revocation Lessons for Claiming Priority to Provisional Applications
- Federal Circuit Report
- McLe Self-Study Article: Bubble, Bubble, Oil-no Trouble?
- AmGen: Markush Practice in 2020
- Ttab Decisions and Developments
- Letter from the Chair
- McLe Self-Study Article: Ethics of Social Media For Lawyers: Where Stunting For the Gram Meets Losing Your Bar Card
- The Licensing Corner
- Upcoming Events
- Copyright News
- Intellectual Property Section Executive Committee 2019-2020
- Case Comments
- 2020 New Matter Author Submission Guidelines
- Letter from the Editor-in-Chief
- Quarterly International Ip Law Update
- Intellectual Property Section Interest Group Representatives 2019-2020
- Contents
- Ip and Art: An International Perspective
- Ninth Circuit Report
- The California Lawyers Association Intellectual Property Alumni
- Online Cle For Participatory Credit
Letter from the Editor-in-Chief
Thomas A. Ward
CommScope
Welcome to the spring edition of New Matter for 2020. The cover art for this issue illustrates the intellectual property (IP) issues arising due to coronavirus. Gilead Sciences’ experimental patented drug remdesivir developed to combat ebola has emerged as a promising candidate against coronavirus. But its patent in China has raised some IP issues.
As a first issue, the Chinese pharma company BrightGene has successfully copied remdesivir and has already mass-produced remdesivir’s active ingredient and is in the process of turning it into finished doses. BrightGene made clear the generic version is still in an R&D phase, and that its final marketing requires permission from the patent holder, Gilead. BrightGene’s board secretary explained that there isn’t any patent infringement issue at this point in China because it’s not selling the product. But manufacturing a copycat to a patented drug at scale without any license is unusual and could create concerns about protection of IP in China.